Prodrug-based nanoparticulate drug delivery strategies for cancer therapy

Trends in Pharmacological Sciences

Volumn 35, Issue 11, 2014, Pages 556-566

  Luo, Cong ^a   Sun, Jin ^a,b   Sun, Bingjun ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

cancer therapy; combination therapy; hybrid nanoassemblies; prodrug nanoassemblies; stimuli responsive

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOHYDRATE; CHITOSAN; CISPLATIN; COPOLYMER; CURCUMIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FIRTECAN; FLUOROURACIL; GEMCITABINE; HEPARIN; HYALURONIC ACID; MACROGOL; MACROGOL 4000; METHOTREXATE; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; POLYAMINOACID; POLYETHYLENE GLYCOL CYCLODEXTRIN COPOLYMER; POLYGLACTIN; POLYPEPTIDE; PRODRUG; PULLULAN; SALINOMYCIN; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CIRCULATION TIME; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RESPONSE; GENE OVEREXPRESSION; MOLECULAR WEIGHT; NANOENCAPSULATION; NANOTECHNOLOGY; PH; REVIEW; SYNTHESIS; ANIMAL; CHEMISTRY; HUMAN; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; PRODRUGS;

EID: 84908362233     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.09.008     Document Type: Review

References (110)

1. L. Bildstein Prodrug-based intracellular delivery of anticancer agents Adv. Drug Deliv. Rev. 63 2011 3 23
2. T. Minko Nanotechnology approaches for personalized treatment of multidrug resistant cancers Adv. Drug Deliv. Rev. 65 2013 1880 1895
3. N. Bertrand Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Deliv. Rev. 66 2014 2 25
4. B. Aslan Nanotechnology in cancer therapy J. Drug Target. 21 2013 904 913
5. J. Sun The holistic 3 M modality of drug delivery nanosystems for cancer therapy Nanoscale 5 2013 845 859
6. K.M. Huttunen Prodrugs - from serendipity to rational design Pharmacol. Rev. 63 2011 750 771
7. Y. Mi Prodrug micelle-based nanomedicine for cancer treatment Nanomedicine 8 2013 1559 1562
8. V. Delplace Recent trends in the design of anticancer polymer prodrug nanocarriers Polym. Chem. 5 2014 1529 1544
9. N. Goodarzi A review of polysaccharide cytotoxic drug conjugates for cancer therapy Carbohydr. Polym. 92 2013 1280 1293
10. J.Y. Fang, and S.A. Al-Suwayeh Nanoparticles as delivery carriers for anticancer prodrugs Expert Opin. Drug Deliv. 9 2012 657 669
11. X. Pang Polymer-drug conjugates: present state of play and future perspectives Drug Discov. Today 18 2013 1316 1322
12. R. Duncan Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt Adv. Drug Deliv. Rev. 61 2009 1131 1148
13. T. Etrych Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy J. Control. Release 154 2011 241 248
14. T. Etrych HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release Mol. Pharm. 7 2010 1015 1026
15. X.Q. Li Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism Chem. Commun. (Camb.) 47 2011 8647 8649
16. M. Hong Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles J. Control. Release 141 2010 22 29
17. L. Zhu Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety Proc. Natl. Acad. Sci. U.S.A. 110 2013 17047 17052
18. X. Hu Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery J. Am. Chem. Soc. 135 2013 17617 17629
19. Z. Zhou Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery Biomaterials 34 2013 5722 5735
20. S. Svenson Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101 J. Control. Release 153 2011 49 55
21. F. Koizumi Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors Cancer Res. 66 2011 10048 10056
22. Y. Mi Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer J. Control. Release 169 2013 185 192
23. H. Xiao A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance Biomaterials 33 2012 6507 6519
24. S. Aryal Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery ACS Nano 4 2010 251 258
25. W. She The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy Biomaterials 34 2013 1613 1623
26. Y. Zhang Core-cross-linked micellar nanoparticles from a linear-dendritic prodrug for dual-responsive drug delivery Polym. Chem. 5 2014 2801 2808
27. F. Zhan Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release Biomacromolecules 12 2011 3612 3620
28. M. Talelli Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin Biomaterials 31 2010 7797 7804
29. T. Nakanishi Development of the polymer micelle carrier system for doxorubicin J. Control. Release 74 2001 295 302
30. H. Xiao Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy J. Control. Release 163 2012 304 314
31. S.Y. Zhang Poly (ethylene oxide)-block-polyphosphester-based paclitaxel conjugates as a platform for ultra-high paclitaxel-loaded multifunctional nanoparticles Chem. Sci. 4 2013 2122 2126
32. Y. Gu Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy Biomacromolecules 14 2013 2772 2780
33. H. Xiao Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo J. Control. Release 173 2014 11 17
34. A.J. van der Vlies Reduction-sensitive thioguanine prodrug micelles Mol. Pharm. 9 2012 2812 2818
35. X. Wei Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors Bioconjug. Chem. 24 2013 658 668
36. M.J. Ernsting A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases J. Control. Release 162 2012 575 581
37. M.J. Ernsting Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models Biomaterials 33 2012 1445 1454
38. C. Chen A prodrug strategy based on chitosan for efficient intracellular anticancer drug delivery Nanotechnology 25 2014 255101
39. W. She Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy Biomaterials 34 2013 2252 2264
40. O.P. Oommen Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach Macromol. Biosci. 14 2013 327 333
41. H. Li High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting J. Biomed. Mater. Res. A 102 2014 150 159
42. Y. Wang pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma Biomaterials 34 2013 7181 7190
43. Y. Wang Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity Bioconjug. Chem. 20 2009 2214 2221
44. D. Xin The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency Pharm. Res. 27 2010 380 389
45. J.A. MacKay Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection Nat. Mater. 8 2009 993 999
46. Y. Yang Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy Biomaterials 34 2013 8430 8443
47. X. Zhang A facile approach for dual-responsive prodrug nanogels based on dendritic polyglycerols with minimal leaching J. Control. Release 174 2014 209 216
48. X. Duan Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram ACS Nano 7 2013 5858 5869
49. S. Harrisson Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization Angew. Chem. Int. Ed. Engl. 52 2013 1678 1682
50. A. Maksimenko Significant tumor growth inhibition from naturally occurring lipid-containing polymer prodrug nanoparticles obtained by the drug-initiated method Chem. Mater. 26 2014 3606 3609
51. D. Trung Bui Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy Biomacromolecules 14 2013 2837 2847
52. W. Wang Tailor-made gemcitabine prodrug nanoparticles from well-defined drug-polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy J. Mater. Chem. B 2 2014 1891 1901
53. G. Li Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery Biomacromolecules 12 2011 2016 2026
54. C. Lee Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 paclitaxel groups and 8 PEG groups Mol. Pharm. 10 2013 4452 4461
55. D. Yang Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy J. Control. Release 161 2012 124 131
56. M. Talelli Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting J. Control. Release 151 2011 183 192
57. T. Hamaguchi Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors Clin. Cancer Res. 16 2010 5058 5066
58. Y. Matsumura Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 91 2004 1775 1781
59. A.G. Cheetham Supramolecular nanostructures formed by anticancer drug assembly J. Am. Chem. Soc. 135 2013 2907 2910
60. Y. Shen Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery J. Am. Chem. Soc. 132 2010 4259 4265
61. J. Wang Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy Adv. Mater. 25 2013 3670 3676
62. H. Zhang Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies J. Control. Release 166 2013 147 158
63. H. Tang Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects Nanomedicine 5 2010 855 865
64. N. Duhem Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo Anticancer Activity Bioconjug. Chem. 25 2013 72 81
65. J.X. Chen Multi-functional envelope-type nanoparticles assembled from amphiphilic peptidic prodrug with improved anti-tumor activity ACS Appl. Mater. Interfaces 6 2014 593 598
66. P. Gou Self-assembling doxorubicin prodrug forming nanoparticles for cancer chemotherapy: synthesis and anticancer study in vitro and in vivo J. Mater. Chem. B 1 2013 284 292
67. A. Maksimenko Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy Cancer Lett. 334 2013 346 353
68. D.T. Bui Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy Chem. Commun. (Camb.) 50 2014 5336 5338
69. J.L. Arias Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics ACS Nano 5 2011 1513 1521
70. J. Caron Combined antitumoral therapy with nanoassemblies of bolaform polyisoprenoyl paclitaxel/gemcitabine prodrugs Polym. Chem. 5 2014 1662 1673
71. J. Caron Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene Adv. Healthc. Mater. 2 2013 172 185
72. S. Mura Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery Bioconjug. Chem. 24 2013 1840 1849
73. L. Shan A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy Biomaterials 33 2012 146 162
74. D. Desmaele Squalenoylation: a generic platform for nanoparticular drug delivery J. Control. Release 161 2012 609 618
75. I.V. Zhigaltsev Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles J. Control. Release 144 2010 332 340
76. K.S. Chu Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity Nano Lett. 14 2014 1472 1476
77. S. Mitra Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier J. Control. Release 74 2001 317 323
78. P.A. McCarron, and M. Hall Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil into poly(lactide-co-glycolide) nanoparticles Int. J. Pharm. 348 2008 115 124
79. M.C. Parrott Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles J. Am. Chem. Soc. 134 2012 7978 7982
80. B.B. Lundberg Preparation and characterization of polymeric pH-sensitive STEALTH(R) nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel Int. J. Pharm. 408 2011 208 212
81. M.L. Forrest Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity Pharm. Res. 25 2008 194 206
82. P.J. Stevens A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug Pharm. Res. 21 2004 2153 2157
83. S.L. Yoong Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin Biomaterials 35 2014 748 759
84. Y. Shi Cyclodextrin capped gold nanoparticles as a delivery vehicle for a prodrug of cisplatin Inorg. Chem. 52 2013 9418 9426
85. S. Dhar Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo Proc. Natl. Acad. Sci. U.S.A. 108 2011 1850 1855
86. X. Xu Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug Proc. Natl. Acad. Sci. U.S.A. 110 2013 18638 18643
87. J. Yang Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy Mol. Pharm. 9 2012 2793 2800
88. N. Graf alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug ACS Nano 6 2012 4530 4539
89. N. Kolishetti Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy Proc. Natl. Acad. Sci. U.S.A. 107 2010 17939 17944
90. Y. Dai In vivo multimodality imaging and cancer therapy by near-infrared light-triggered trans-platinum pro-drug-conjugated upconversion nanoparticles J. Am. Chem. Soc. 135 2013 18920 18929
91. Y.M. Bae Enhanced splicing correction effect by an oligo-aspartic acid-PNA conjugate and cationic carrier complexes J. Control. Release 175 2014 54 62
92. S.M. Ansell Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates J. Med. Chem. 51 2008 3288 3296
93. Z. Ge, and S. Liu Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance Chem. Soc. Rev. 42 2013 7289 7325
94. J. Hu, and S. Liu Engineering responsive polymer building blocks with host-guest molecular recognition for functional applications Acc. Chem. Res. 47 2014 2084 2095
95. Q. Yin Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor Adv. Drug Deliv. Rev. 65 2013 1699 1715
96. J.R. McDaniel Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation Angew. Chem. Int. Ed. Engl. 52 2013 1683 1687
97. S.R. MacEwan Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery Nanomedicine 5 2010 793 806
98. R. Tang Block copolymer micelles with acid-labile ortho ester side-chains: synthesis, characterization, and enhanced drug delivery to human glioma cells J. Control. Release 151 2011 18 27
99. J.C. Eloi Stimulus-responsive self-assembly: reversible, redox-controlled micellization of polyferrocenylsilane diblock copolymers J. Am. Chem. Soc. 133 2011 8903 8913
100. Y.W. Cho Complex adaptive therapeutic strategy (CATS) for cancer J. Control. Release 175 2014 43 47
101. M.J. Sailor, and J.H. Park Hybrid nanoparticles for detection and treatment of cancer Adv. Mater. 24 2012 3779 3802
102. X. Wan Photo-degradable, protein-polyelectrolyte complex-coated, mesoporous silica nanoparticles for controlled co-release of protein and model drugs Macromol. Rapid Commun. 34 2013 341 347
103. C. Luo Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy J. Control. Release 176 2014 94 103
104. M. Wang, and M. Thanou Targeting nanoparticles to cancer Pharmacol. Res. 62 2010 90 99
105. C.S. Mitsiades Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma J. Clin. Oncol. 29 2011 1916 1923
106. A. Eldar-Boock Nano-sized polymers and liposomes designed to deliver combination therapy for cancer Curr. Opin. Biotech. 24 2013 682 689
107. T. Lammers Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy Nano Today 5 2010 197 212
108. F. Greco, and M.J. Vicent Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Deliv. Rev. 61 2009 1203 1213
109. S.R. Park Safety and feasibility of targeted agent combinations in solid tumours Nat. Rev. Clin. Oncol. 10 2013 154 168
110. N.N. Li A macromolecular prodrug strategy for combinatorial drug delivery J. Colloid Interface Sci. 417 2014 301 309